Why the study?
Does modified CPVA reduce the risk of developing incessant AT compared to CPVA in patients undergoing ablation of atrial fibrillation?
Does modified CPVA reduce the risk of developing incessant AT compared to CPVA in patients undergoing ablation of atrial fibrillation?
Modified CPVA maintains efficacy for AF prevention while reducing the risk of iatrogenic incessant atrial tachycardia compared to standard CPVA.
May support modified CPVA to lower incessant AT risk in AF ablation; leaves open randomized confirmation before practice change.
Modified CPVA is as effective as CPVA in preventing AF but is associated with a lower risk of developing incessant AT.
No takes yet. Share an insight, caveat, or question.
Pappone et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: